Pathology of Hepatitis c Nephropathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-11-30

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hepatitis c associated glomerulonephritis is an immune complex disease that occurs in 21% of patients who have HCV infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevalence of Hepatitis c Virus Infection Among Rheumatological Patients

NCT03587714

Hepatitis C

COMPLETED

Effects of Direct Antiviral Agents on Hepatitis C Virus Arthropathy

NCT03226717

Hepatitis C

UNKNOWN

Alpha -1- Microglobulin (α1M) as an Early Biomarker in Renal Extrahepatic Manifestations of HCV-infection

NCT05276700

Renal Injury HCV

UNKNOWN

Changes in High Sensitive C Reactive Protien With Different Treatment Modalities in Acute Pancreatitis

NCT03740685

Pancreatitis, Acute

UNKNOWN

Prevalence and Pathological Features of C3 Dominant Glomerulonephritis Among Egyptian Population

NCT06126471

C3 Nephropathy

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hepatitis C virus infection is a major public health problem with an estimated global prevalence of 3% and an estimated 5-20% of infected patients will develop liver cirrhosis .The Prevalence of Hepatitis C infection in end stage renal disease is greater than in the general population especially in those on hemodialysis which reflects nosocomial transmission of the disease in the hemodialysis environment.

Hepatitis C associated glomerulonephritis is an immune complex disease that occurs in 21% of patients who have HCV infection. It most commonly presents as membranoproliferative and mixed cryoglobulinemia It characterized by an indolent course in one third of patients , remission in another third and relapsing course in the remaining patients with potential progression to advanced chronic kidney disease.

mechanism of injury : Chronic Hepatitis C is primarily associated with type II cryoglobulinemia , in which the primary mechanism of injury is vasculitis that occurs via immune complex deposition.

hepatitis C virus related glomerular disease :

Type I membranoproliferative was the most common finding associated with mixed cryoglobulinemia but other forms of glomerulonephritis were associated with Hepatitis c like mesangial glomerulonephritis,focal and segmental glomerulonephritis,minimal change nephropathy,membranous nephropathy , Fibrillary glomerulonephritis,immunotactoid glomerulopathy,IgA nephropathy, vasculitic renal involvement ,poly arteritis nodosa and interstitial nephritis .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cryoglobulinaemia Due to Chronic Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

study group

patients with hepatitis c nephropathy detected by lab and renal biopsy

renal biopsy

Intervention Type DIAGNOSTIC_TEST

needle biopsy will be taken from the kidney tissue then, diagnosed

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

renal biopsy

needle biopsy will be taken from the kidney tissue then, diagnosed

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* it will be conducted on chronic hepatitis C patients with chronic kidney disease .
* The participants will be classified according to their estimated GFR by modified MDRD equation and
* they will be recruited from the renal unit of internal medicine, Assiut University Hospitals and assiut hepatitis viruses unit-ministry of health, Egypt.

Exclusion Criteria

Patients will be excluded if the underlying causes of CRF are as follows:

chronic pyelonephritis,obstructive uropathy,Polycystic kidney disease,Patients with ESRD on regular hemodialysis,patients with advanced liver cirrhosis,hepatocellular carcinoma,Patients on steroids or immunosuppressive drugs and Solitary kidney.

Minimum Eligible Age

20 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No